<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512439437</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512439437</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Behavioural symptoms and impairments in multiple sclerosis: a systematic review and meta-analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Rosti-Otajärvi</surname><given-names>Eija</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512439437">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hämäläinen</surname><given-names>Päivi</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512439437">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512439437"><label>1</label>Department of Neurology and Rehabilitation, Tampere University Hospital, Finland.</aff>
<aff id="aff2-1352458512439437"><label>2</label>Masku Neurological Rehabilitation Centre, Finland.</aff>
<author-notes>
<corresp id="corresp1-1352458512439437">Eija Rosti-Otajärvi, Tampere University Hospital, Department of Neurology and Rehabilitation, PO Box 2000, 33521 Tampere, Finland. Email: <email>eija.rostiotajarvi@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>31</fpage>
<lpage>45</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>8</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>1</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Behavioural problems are not well recognized in multiple sclerosis (MS). In this review we aimed to evaluate the prevalence of behavioural symptoms and impairments in MS. A systematic search was carried out from MEDLINE, PsycINFO, Web of Science, CINAHL and COCHRANE. In total, 23 studies (1831 participants) were identified. Based on the literature search, behavioural symptoms and impairments are observed in MS. Aggression (23%), apathy (22%), euphoria (12%) and lack of insight (11%) were the most frequent symptoms, and adjustment disorder (17%) the most frequent impairment. Severe mental disorders are more infrequent than changes in behaviour, manner of reaction, and way of action. In conclusion the objective behavioural impairments and especially subjective symptoms are present in patients with MS. These manifestations should be taken into account in the diagnostics and treatment of the disease.</p>
</abstract>
<kwd-group>
<kwd>behaviour</kwd>
<kwd>behavioural impairment</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>MS</kwd>
<kwd>neuropsychiatry</kwd>
<kwd>neuropsychiatric disorder</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458512439437" sec-type="intro">
<title>Introduction</title>
<p>Neuropsychiatric symptoms can be divided into cognitive and behavioural symptoms.<sup><xref ref-type="bibr" rid="bibr1-1352458512439437">1</xref></sup> Cognitive dysfunction is well documented in multiple sclerosis (MS) and occurs in up to 60% of MS patients.<sup><xref ref-type="bibr" rid="bibr2-1352458512439437">2</xref></sup> MS-related cognitive deficits are heterogeneous, impairments in information-processing speed, attention, and memory being the most frequent.<sup><xref ref-type="bibr" rid="bibr2-1352458512439437">2</xref></sup> While cognitive deficits are well documented in MS, behavioural impairments have received less attention and are generally not a part of the health status assessment of patients with MS. According to Feinstein,<sup><xref ref-type="bibr" rid="bibr3-1352458512439437">3</xref></sup> for example depression, apathy, lability, euphoria, pseudobulbar affect, anosognosia, disinhibition, inappropriate social behaviour, and personality changes can be observed in MS. However, the frequency of behavioural symptoms and impairments in MS is not well known.</p>
<p>Most previous studies on neuropsychiatric symptoms in MS have focused on Axis I of DSM-IV disorders and have found relatively high rates in patients with MS. Depression is the most extensively studied and the most common neuropsychiatric manifestation in MS, with lifetime prevalence rates of about 50%.<sup><xref ref-type="bibr" rid="bibr4-1352458512439437">4</xref></sup> Irritability, frustration and discouragement are more likely to accompany low mood in MS patients than feelings of guilt and low self-esteem.<sup><xref ref-type="bibr" rid="bibr1-1352458512439437">1</xref></sup> The results of a meta-analysis including 41 original depression studies revealed that a majority of patients with MS have more depressive symptoms than healthy controls.<sup><xref ref-type="bibr" rid="bibr5-1352458512439437">5</xref></sup> However, the results of the same meta-analysis were more heterogeneous with higher, lower and equivalent levels of depressive symptoms when the prevalence rates of other diseases were compared with those of MS.<sup><xref ref-type="bibr" rid="bibr5-1352458512439437">5</xref></sup></p>
<p>Behavioural self-regulation refers to the abilities by which people control their thoughts, feelings, and behaviours.<sup><xref ref-type="bibr" rid="bibr3-1352458512439437">3</xref></sup> Disorders in personality and behavioural regulation have received less attention in the study of neuropsychiatric symptoms in MS. To our knowledge, there is no previous quantitative meta-analysis in the field. Studies on neuropsychiatric disturbances in MS have focused on one or only a few psychiatric symptoms such as depression or anxiety. Less is known about the range of neuropsychiatric symptoms occurring in patients assessed simultaneously for a wide range of neuropsychiatric disorders using multi-symptom assessment methods.</p>
<p>The origin of neuropsychiatric manifestations and behavioural changes in MS is poorly understood; a complex interplay of biological, disease-related, behavioural and psychosocial factors has been suggested to contribute to the pathophysiology.<sup><xref ref-type="bibr" rid="bibr4-1352458512439437">4</xref></sup> Two different mechanisms have been suggested to be present: 1) white matter dysfunction and disconnection within frontotemporal networks modifying patients’ behaviour;<sup><xref ref-type="bibr" rid="bibr6-1352458512439437">6</xref></sup> and 2) maladapted coping responses, which may occur during any chronic illness characterized by an unpredictable functional decline with considerable psychological implications.<sup><xref ref-type="bibr" rid="bibr7-1352458512439437">7</xref></sup> The unpredictable course of the disease poses a significant challenge to how patients think about themselves and how others perceive them. Thus, the origin of behavioural modifications presumably lies in both neuropathological changes and in psychological reactions.</p>
<p>The focus of the present review was on the subjective and objective dysfunction of behavioural regulation in MS, and the aims were twofold. The first aim was to quantitatively evaluate the prevalence of behavioural impairments in MS by combining the results of controlled studies with meta-analyses. In order to differentiate general illness effects from MS-specific neuropsychiatric symptoms, patients with other diseases were used as controls, in addition to healthy controls. The second aim was to provide a cross-section and description of the evaluation methods used to describe MS-related behavioural impairments in the literature.</p>
</sec>
<sec id="section2-1352458512439437" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1352458512439437">
<title>Inclusion criteria</title>
<p>Studies which fulfilled the inclusion criteria described in <xref ref-type="table" rid="table1-1352458512439437">Table 1</xref> were included. MS diagnosis had to be clinically definite according to known criteria, such as those of Poser et al.<sup><xref ref-type="bibr" rid="bibr8-1352458512439437">8</xref></sup> or McDonald et al.<sup><xref ref-type="bibr" rid="bibr9-1352458512439437">9</xref></sup> In order to be included in the review, behavioural impairments should have been evaluated in the study. Behavioural impairments were defined as subjective symptoms or objective disorders included in the following DSM-IV categories: adjustment, anxiety, dissociative, impulse-control, personality, psychotic or somatoform disorders. Symptoms or disorders of the DSM-IV categories of eating, sexual, and sleep (neurovegetative symptoms/disorders) as well as mood disorders were excluded. Original studies with controls, either healthy ones or patients with diseases other than MS were included, whereas case-control settings (e.g. MS patients with and without behavioural impairments) were excluded. The outcome measures had to be clinical methods measuring behavioural impairments, and quantitative data on these methods had to be reported in the study.</p>
<table-wrap id="table1-1352458512439437" position="float">
<label>Table 1.</label>
<caption>
<p>Selection criteria for the studies.</p>
</caption>
<graphic alternate-form-of="table1-1352458512439437" xlink:href="10.1177_1352458512439437-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Definition</th>
<th align="left">Included</th>
<th align="left">Excluded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient population</td>
<td>1) MS patients<break/>2) Studies concerning MS patients and other patient populations when the results of MS patients can be separated from those of other patients</td>
<td>1) Other than MS patients<break/>2) Studies concerning MS patients and other patient populations when the results of MS patients cannot be separated from those of other patients</td>
</tr>
<tr>
<td>Target of the study</td>
<td>1) Behavioural impairments (subjective symptoms/objective disorders included in DSM-IV categories: adjustment, anxiety, dissociative, impulse-control, personality, psychotic or somatoform disorders)<break/>2) Behavioural impairments in addition to other impairments (e.g. depression) when the results of behavioural impairments could be separated from the reporting of the results</td>
<td>1) Other than behavioural impairments<break/>2) The results of behavioural impairments not reported</td>
</tr>
<tr>
<td>Research setting</td>
<td>Controlled studies (healthy controls or patients with other disease than MS)</td>
<td>1) Non-controlled studies<break/>2) Case-control-settings</td>
</tr>
<tr>
<td>Assessment methods</td>
<td>1) Behavioural impairments measured with clinical outcome methods (questionnaires, clinical interviews etc.)<break/>2) Quantitative data on behavioural assessment methods reported</td>
<td>1) Behavioural impairments measured with other than clinical outcome methods<break/>2) Quantitative data on behavioural assessment methods not reported</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section4-1352458512439437">
<title>Literature search</title>
<p>The literature search was carried out from MEDLINE, PsycINFO, Web of Science (WOS), CINAHL and COCHRANE for relevant studies to April 2011. The search terms for behavioural impairments were created as subjective symptoms or objective disorders related to dysfunction of behavioural regulation. The search was carried out by combining the subject headings: 1) <italic>MS disease</italic> (multiple sclerosis, MS, demyelinating disease, demyelinating autoimmune disease, autoimmune disease); 2) <italic>behavioural impairments</italic> (neuropsychiatry, pseudobulbar affect, euphoria, pathological laughing, pathological crying, behaviour disorder, behaviour change, behavioural symptom, behavioural control, irritability, anosognosia, lack of insight, disinhibited behaviour, disinhibition, apathy, blunted emotions, indifference, emotional lability, lability, personality change, personality disorder, personality disturbance, impulsive behaviour, self-regulation disorder, character change, unrealistic optimism, inappropriate social behaviour); and 3) <italic>research setting</italic> (controlled clinical trial, clinical trial, experimental clinical trial, controlled trial, controlled study) with free text keywords. Studies comprising human subjects and written in English, Finnish, Swedish, or German were included. In addition to electronic searches, the references of included studies were examined for any additional relevant literature.</p>
<p>Two reviewers (ER and PH) independently assessed study relevance and selection using predetermined inclusion criteria (<xref ref-type="table" rid="table1-1352458512439437">Table 1</xref>). In the first phase, based on the abstracts, one reviewer (ER) excluded articles which obviously did not cover patients with MS and behavioural impairments. Articles with any uncertainty were selected for the next phase. In the second phase, based on the abstracts, two independent reviewers (ER and PH) evaluated whether selection criteria were fulfilled, and which articles should be searched for full text evaluation. In the third phase, the full texts of the selected articles were evaluated by two independent reviewers. Neither of the reviewers was an author of or otherwise involved in the studies included in the review. The journal title, names and institutions of the authors, sources of funding and results were available for the reviewers in every phase of the review.</p>
</sec>
<sec id="section5-1352458512439437">
<title>Data extraction</title>
<p>The two review authors (ER and PH) extracted the data for the final content of the information. One of the authors (ER) tabulated the data, which was checked out and completed by the other author (PH). Consensus was reached on every item included in the final tables. Studies with multiple MS groups (e.g. cognitively impaired and intact MS patients) were included and analysed by pooling the data into a single MS group. MS groups were pooled in two of the included studies.<sup><xref ref-type="bibr" rid="bibr10-1352458512439437">10</xref>,<xref ref-type="bibr" rid="bibr11-1352458512439437">11</xref></sup></p>
<p>The data concerning 1) <italic>participants</italic> (number, age, years of education, gender, MS disease course, severity and duration of the disease); 2) <italic>outcome measures</italic>; and 3) <italic>results</italic>, were tabulated from the studies. For dichotomous data, the number of participants with certain neuropsychiatric disorder and the number of participants in each group were reported. Similarly, for continuous data, the mean and standard deviation (SD) of each outcome variable and the number of participants in each group were reported.</p>
</sec>
<sec id="section6-1352458512439437">
<title>Meta-analyses</title>
<p>Meta-analyses were performed using RevMan 5.1.<sup><xref ref-type="bibr" rid="bibr12-1352458512439437">12</xref></sup> for two subgroups: 1) MS patients versus healthy controls (<italic>number of studies</italic> = 17); and 2) MS patients versus other patients (<italic>n</italic> = 6). Dichotomous outcome variables were analysed using odd ratios (OR), and continuous variables using mean differences (MD). The standardized mean difference (SMD) was calculated when continuous data were based on the results derived from different scales. For every effect, 95% confidence intervals (CI) were calculated. The <italic>I</italic><sup>2</sup> statistic was used to evaluate the heterogeneity of study variables. <italic>I</italic><sup>2</sup> values of 25%, 50% and 75% corresponded to low, medium and high levels of heterogeneity, respectively. When heterogeneity was not found, a fixed-effects model was adopted. When the <italic>I</italic><sup>2</sup> statistic was significant at ≥ 50% of results, estimates for the effects were calculated using a random-effects model (providing broader confidence intervals than a fixed-effect model). In addition, prevalence of behavioural symptoms and impairments was reported when available.</p>
</sec>
</sec>
<sec id="section7-1352458512439437" sec-type="results">
<title>Results</title>
<sec id="section8-1352458512439437">
<title>Article identification and selection</title>
<p>The literature search process is described in <xref ref-type="fig" rid="fig1-1352458512439437">Figure 1</xref>. In total, 23 studies were included and listed in the references.<sup><xref ref-type="bibr" rid="bibr10-1352458512439437">10</xref>,<xref ref-type="bibr" rid="bibr11-1352458512439437">11</xref>,<xref ref-type="bibr" rid="bibr13-1352458512439437">13</xref>-<xref ref-type="bibr" rid="bibr33-1352458512439437">33</xref></sup> Based on the full text, 11 articles were excluded. Reasons for exclusion are reported in <xref ref-type="fig" rid="fig1-1352458512439437">Figure 1</xref>. Included studies were published between 1969 and 2010. They had been conducted in nine different countries: 13 in the United States, two each in Italy and Great Britain, and one in Hungary, Norway, Israel, Australia, Switzerland, and Canada. All the studies were written in English.</p>
<fig id="fig1-1352458512439437" position="float">
<label>Figure 1.</label>
<caption>
<p>Flow chart of the study selection process.</p>
</caption>
<graphic xlink:href="10.1177_1352458512439437-fig1.tif"/>
</fig>
</sec>
<sec id="section9-1352458512439437">
<title>Participants</title>
<p>There were 1831 participants, of whom 1117 were MS patients, 437 healthy controls and 277 patients with other diagnoses. Controls with other diagnosis had systemic lupus erythematosus (SLE; <italic>n</italic> = 1 study), chronic fatigue syndrome (<italic>n</italic> = 2 studies), systemic inflammatory disorders (<italic>n</italic> = 1 study), muscular dystrophy (<italic>n</italic> = 1 study), and rheumatic or neurological diseases not involving the brain (<italic>n</italic> = 1 study). The number of participants per study varied from 31–164 (mean 80). The proportion of women among the participants varied from 45–91% (mean 66%; gender distribution was not reported in all studies). The mean age of the participants varied from 31.2–47.7 years (mean 39.9) and mean years of education from 9.4–15.3 (mean 14.2; mean age and years of education were not reported in all studies). Most of the participants (46%) had a relapsing–remitting course of the disease (<italic>n</italic> = 515; course was not reported in all studies). The mean Expanded Disability Status Scale (EDSS) score varied from 1.5–5.1 (mean 3.2) among patients, with mean duration of disease from 2.6–12.0 years (mean 8.1; EDSS scores and duration of the disease were not reported in all studies). MS and control groups did not differ with regard to demographic factors in the studies. However, the controls were better educated than MS patients in one study.<sup><xref ref-type="bibr" rid="bibr18-1352458512439437">18</xref></sup> In addition, MS patients were older than controls in one study.<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup></p>
</sec>
<sec id="section10-1352458512439437">
<title>Behavioural symptoms and impairments</title>
<sec id="section11-1352458512439437">
<title>MS patients versus healthy controls</title>
<p>The results of the meta-analyses and prevalence rates of behavioural symptoms and impairments are summarized in <xref ref-type="table" rid="table2-1352458512439437">Table 2</xref>. Meta-analyses revealed that patients with MS had significantly more behavioural symptoms than healthy controls in 13 out of 20 analyses. Specifically, MS patients were found to show more irritability (<italic>p</italic> &lt; 0.00001), lack of insight (<italic>p</italic> &lt; 0.00001), somatization (<italic>p</italic> &lt; 0.00001), obsessiveness (<italic>p</italic> &lt; 0.00001), alexithymia (<italic>p</italic> &lt; 0.00001), lability (<italic>p</italic> = 0.0001), euphoria (<italic>p</italic> = 0.0002), apathy (<italic>p</italic> = 0.001), neuroticism (<italic>p</italic> = 0.001), disinhibition (<italic>p</italic> = 0.006), aggression (<italic>p</italic> = 0.006), and problems in affective prosody (<italic>p</italic> = 0.0002) and social cognition/theory of mind (<italic>p</italic> = 0.003) than healthy controls. Respectively, meta-analyses revealed significantly more behavioural impairments than healthy controls in three out of 11 analyses. Specifically, patients with MS were found to show more paranoid (<italic>p</italic> = 0.03) and borderline personality (<italic>p</italic> = 0.03), as well as adjustment disorders (<italic>p</italic> = 0.05) than healthy controls.</p>
<table-wrap id="table2-1352458512439437" position="float">
<label>Table 2.</label>
<caption>
<p>Behavioural symptoms and impairments among MS patients versus healthy controls and among MS patients versus other patients.</p>
</caption>
<graphic alternate-form-of="table2-1352458512439437" xlink:href="10.1177_1352458512439437-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Outcome</th>
<th align="center" colspan="3">MS patients versus healthy controls</th>
<th align="center" colspan="3">MS patients versus other patients</th>
</tr>
<tr>
<th/>
<th align="center">Studies Participants</th>
<th align="center">Effect estimate, <italic>p</italic>-value</th>
<th align="center">Prevalence</th>
<th align="center">Studies Participants</th>
<th align="center">Effect estimate, <italic>p</italic>-value</th>
<th align="center">Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="7"><bold>BEHAVIOURAL SYMPTOMS</bold></td>
</tr>
<tr>
<td>Irritability</td>
<td>3 (Diaz-Olavarrieta 1999<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup>, Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>, Benedict 2001<sup><xref ref-type="bibr" rid="bibr15-1352458512439437">15</xref></sup>) 333 (239 MS vs. 94 HC)</td>
<td>0.72 [0.47, 0.97], <italic>p</italic> &lt; 0.00001 <sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">*</xref></sup></td>
<td>35% vs. 8% (Diaz-Olavarrieta 1999<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup>) 61% vs. 24% (Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>) Mean: 48% vs. 16%</td>
<td>3 (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>, Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>, Surridge 1969<sup><xref ref-type="bibr" rid="bibr33-1352458512439437">33</xref></sup>) 404 (268 MS vs. 136 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">a</xref></sup>,<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>,<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">c</xref></sup>)</td>
<td>2.94 [0.87, 9.95], <italic>p</italic> = 0.08<sup>#</sup></td>
<td>42% vs. 15% (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) 33% vs. 32% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 20% vs. 3% (Surridge 1969<sup><xref ref-type="bibr" rid="bibr33-1352458512439437">33</xref></sup>) Mean: 32% vs. 17%</td>
</tr>
<tr>
<td>Apathy</td>
<td>2 (Diaz-Olavarrieta 1999<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup>, Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>) 169 (119 MS vs. 50 HC)</td>
<td>0.61 [0.24, 0.98], <italic>p</italic> = 0.001<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>35% vs. ? (Chiaravalloti 2003<sup><xref ref-type="bibr" rid="bibr17-1352458512439437">17</xref></sup>) 20% vs. 0% (Diaz-Olavarrieta 1999<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup>) 19% vs. 4% (Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>) Mean: 25% vs. 2%</td>
<td>3 (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>, Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>, Surridge 1969<sup><xref ref-type="bibr" rid="bibr33-1352458512439437">33</xref></sup>) 404 (268 MS vs. 136 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">a</xref></sup>,<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>,<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">c</xref></sup>)</td>
<td>3.32 [1.62, 6.80], <italic>p</italic> = 0.001<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>31% vs. 10% (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) 19% vs. 11% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 9% vs. 0% (Surridge 1969<sup><xref ref-type="bibr" rid="bibr33-1352458512439437">33</xref></sup>) Mean: 20% vs. 7%</td>
</tr>
<tr>
<td>Disinhibition</td>
<td>4 (Diaz-Olavarrieta 1999<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup>, Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>, Grigsby 1994<sup><xref ref-type="bibr" rid="bibr25-1352458512439437">25</xref></sup>, Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 255 (162 MS vs. 93 HC)</td>
<td>0.99 [0.29, 1.70], <italic>p</italic> = 0.006<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">‡</xref></sup></td>
<td>19% vs. ? (Chiaravalloti 2003<sup><xref ref-type="bibr" rid="bibr17-1352458512439437">17</xref></sup>) 13% vs. 0% (Diaz-Olavarrieta 1999<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup>) 25% vs. 4% (Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>) Mean: 19% vs. 2%</td>
<td>2 (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>, Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 257 (160 MS vs. 97 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">a</xref></sup>,<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>)</td>
<td>1.97 [0.69, 5.68], <italic>p</italic> = 0.21<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>7% vs. 3% (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) 12% vs 9% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 10% vs. 6%</td>
</tr>
<tr>
<td>Lability</td>
<td>1 (Haiman 2008<sup><xref ref-type="bibr" rid="bibr10-1352458512439437">10</xref></sup>) 33 (22 MS vs. 11 HC)</td>
<td>5.50 [2.68, 8.32], <italic>p</italic> = 0.0001<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>Not reported</td>
<td>1 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 122 (74 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>)</td>
<td>1.36 [0.64, 2.91], <italic>p</italic> = 0.42<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>41% vs. 34% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 41% vs. 34%</td>
</tr>
<tr>
<td>Euphoria</td>
<td>2 (Diaz-Olavarrieta 1999,<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup>Fishman 2004)<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup> 169 (119 MS vs. 50 HC)</td>
<td>0.60 [0.29, 0.91], <sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">p</xref></sup> = 0.0002<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>13% vs. 0% (Diaz-Olavarrieta 1999)<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup> 15% vs. 0% (Fishman 2004)<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup> Mean: 14% vs. 0%</td>
<td>2 (Figved 200521, Surridge 196933) 282 (194 MS vs. 88 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">a</xref></sup>,<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">c</xref></sup>)</td>
<td>6.32 [1.17, 34.13], <italic>p</italic> = 0.03<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>5% vs. 3% (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) 15% vs. 0% (Surridge 1969<sup><xref ref-type="bibr" rid="bibr33-1352458512439437">33</xref></sup>) Mean: 10% vs. 2%</td>
</tr>
<tr>
<td>Lack of insight</td>
<td>1 (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 55 (20 MS vs. 35 HC)</td>
<td>2.50 [1.99, 3.01], <italic>p</italic> &lt; 0.00001<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>Not reported</td>
<td>2 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>, Surridge 1969<sup><xref ref-type="bibr" rid="bibr33-1352458512439437">33</xref></sup>) 269 (182 MS vs. 87 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>,<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">c</xref></sup>)</td>
<td>4.19 [1.06, 16.47], <italic>p</italic> = 0.04<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>10% vs. 5% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 11% vs. 0% (Surridge 1969<sup><xref ref-type="bibr" rid="bibr33-1352458512439437">33</xref></sup>) Mean: 11% vs. 5%</td>
</tr>
<tr>
<td>Social withdrawal</td>
<td>2 (Benedict 2001<sup><xref ref-type="bibr" rid="bibr15-1352458512439437">15</xref></sup>, Gioia 2009<sup><xref ref-type="bibr" rid="bibr24-1352458512439437">24</xref></sup>) 79 (52 MS vs. 27 HC)</td>
<td>0.24 [-1.40, 1.88], <italic>p</italic> = 0.77<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">‡</xref></sup></td>
<td>Not reported</td>
<td>2 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>, Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 209 (116 MS vs. 93 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>,<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>2.22 [0.88, 5.61], <italic>p</italic> = 0.09<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>22% vs. 9% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 7% vs. 7% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) Mean: 15% vs. 8%</td>
</tr>
<tr>
<td>Aggression</td>
<td>2 (Daly 2001<sup><xref ref-type="bibr" rid="bibr18-1352458512439437">18</xref></sup>, Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>) 149 (99 MS vs. 50 HC)</td>
<td>0.63 [0.27, 0.99], <italic>p</italic> = 0.0006 <sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">*</xref></sup></td>
<td>37% vs. 16% (Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>) Mean: 37% vs. 16%</td>
<td>3 (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>, Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 257 (160 MS vs. 97 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">a</xref></sup>,<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>)</td>
<td>6.04 [1.77, 20.61], <italic>p</italic> = 0.004<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>23% vs. 5% (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) 9% vs. 2% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 16% vs. 4%</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>2 (Diaz-Olavarrieta 1999,<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup> Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>) 169 (119 MS vs. 50 HC)</td>
<td>0.14 [-0.23, 0.52], <italic>p</italic> = 0.45<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">§</xref></sup></td>
<td>10% vs. 0% (Diaz-Olavarrieta 1999<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup>) 0% vs. 0% (Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>) Mean: 5% vs. 0%</td>
<td>1 (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) 135 (86 MS vs. 49 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">a</xref></sup>)</td>
<td>-0.01 [-0.07, 0.05], <italic>p</italic> = 0.73<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>0% vs. 5% (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) Mean: 0% vs. 5%</td>
</tr>
<tr>
<td>Delusions</td>
<td>2 (Diaz-Olavarrieta 1999<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup>, Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>) 169 (119 MS vs. 50 HC)</td>
<td>0.14 [-0.01, 0.29], <italic>p</italic> = 0.07<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>7% vs. 0% (Diaz-Olavarrieta 1999<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup>) 3% vs. 0% (Fishman 2004<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>) Mean: 5% vs. 0%</td>
<td>1 (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) 135 (86 MS vs. 49 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">a</xref></sup>)</td>
<td>0.41 [0.09, 1.90], <italic>p</italic> = 0.25<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>4% vs. 8% (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) Mean: 4% vs. 8%</td>
</tr>
<tr>
<td>Paranoid ideation</td>
<td>1 (Daly 2001<sup><xref ref-type="bibr" rid="bibr18-1352458512439437">18</xref></sup>) 49 (24 MS vs. 25 HC)</td>
<td>0.80 [-0.13, 1.73], <italic>p</italic> = 0.09<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>Not reported</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Aberrant motor behaviour</td>
<td>2 (Diaz-Olavarrieta 1999,<sup><xref ref-type="bibr" rid="bibr19-1352458512439437">19</xref></sup> Fishman 2004) <sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup>169 (119 MS vs. 50 HC)</td>
<td>0.13 [-0.00, 0.27], <italic>p</italic> = 0.06<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>9% vs. 0% (Diaz-Olavarrieta 1999) 194% vs. 0% (Fishman 2004)<sup><xref ref-type="bibr" rid="bibr22-1352458512439437">22</xref></sup> Mean: 7% vs. 0%</td>
<td>1 (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) 135 (86 MS vs. 49 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">a</xref></sup>)</td>
<td>0.20 [0.01, 0.39], <italic>p</italic> = 0.04<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>6% vs. 0% (Figved 2005<sup><xref ref-type="bibr" rid="bibr21-1352458512439437">21</xref></sup>) Mean: 6% vs. 0%</td>
</tr>
<tr>
<td>Blunted emotions</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 122 (74 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>)</td>
<td>0.52 [0.16, 1.64], <italic>p</italic> = 0.26<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>9% vs. 14% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 9% vs. 14%</td>
</tr>
<tr>
<td>Somatization</td>
<td>1 (Daly 2001<sup><xref ref-type="bibr" rid="bibr18-1352458512439437">18</xref></sup>) 49 (24 MS vs. 25 HC)</td>
<td>4.50 [3.48, 5.52], <italic>p</italic> &lt; 0.00001<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>Not reported</td>
<td>1 (Ron 1989<sup><xref ref-type="bibr" rid="bibr32-1352458512439437">32</xref></sup>) 164 (116 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">e</xref></sup>)</td>
<td>1.26 [0.05, 31.47], <italic>p</italic> = 0.89<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>1% vs. 0% (Ron 1989<sup><xref ref-type="bibr" rid="bibr32-1352458512439437">32</xref></sup>) Mean: 1% vs. 0%</td>
</tr>
<tr>
<td>Obsessiveness</td>
<td>1 (Daly 2001<sup><xref ref-type="bibr" rid="bibr18-1352458512439437">18</xref></sup>) 49 (24 MS vs. 25 HC)</td>
<td>3.50 [2.04, 4.96], <italic>p</italic> &lt; 0.00001<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>Not reported</td>
<td>1 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 122 (74 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>1.50 [0.49, 4.63], <italic>p</italic> = 0.48<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>16% vs. 11% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 16% vs. 11%</td>
</tr>
<tr>
<td>Neuroticism</td>
<td>2 (Benedict 2001<sup><xref ref-type="bibr" rid="bibr15-1352458512439437">15</xref></sup>, Gioia 2009)<sup><xref ref-type="bibr" rid="bibr24-1352458512439437">24</xref></sup> 79 (52 MS vs. 27 HC)</td>
<td>0.80 [0.32, 1.29], <italic>p</italic> = 0.001 <sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">*</xref></sup></td>
<td>Not reported</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Psychoticism</td>
<td>2 (Daly 2001<sup><xref ref-type="bibr" rid="bibr18-1352458512439437">18</xref></sup>, Gioia 2009<sup><xref ref-type="bibr" rid="bibr24-1352458512439437">24</xref></sup>) 80 (42 MS vs. 38 HC)</td>
<td>0.17 [-0.86, 1.21], <italic>p</italic> = 0.74<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">‡</xref></sup></td>
<td>Not reported</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Alexithymia</td>
<td>1 (Johnson 2001<sup><xref ref-type="bibr" rid="bibr29-1352458512439437">29</xref></sup>) 32 (16 MS vs. 16 HC)</td>
<td>15.00 [13.12, 16.88], <italic>p</italic> &lt; 0.00001<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>Not reported</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Lack of empathy</td>
<td>3 (Banati 2000<sup><xref ref-type="bibr" rid="bibr13-1352458512439437">13</xref></sup>, Benedict 2001<sup><xref ref-type="bibr" rid="bibr15-1352458512439437">15</xref></sup>, Daly 2001<sup><xref ref-type="bibr" rid="bibr18-1352458512439437">18</xref></sup>) 172 (98 MS vs. 74 HC)</td>
<td>0.42 [-0.51, 1.35], <italic>p</italic> = 0.38‡</td>
<td>Not reported</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Deficiencies in social cognition/theory of mind</td>
<td>3 (Banati 2000<sup><xref ref-type="bibr" rid="bibr13-1352458512439437">13</xref></sup>, Ouellet 2010<sup><xref ref-type="bibr" rid="bibr11-1352458512439437">11</xref></sup>, Henry 2009<sup><xref ref-type="bibr" rid="bibr26-1352458512439437">26</xref></sup>) 526 (311 MS vs. 215 HC)</td>
<td>0.52 [0.17, 0.86], <italic>p</italic> = 0.003<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">‡</xref></sup></td>
<td>Not reported</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Aprosodia</td>
<td>1 (Beatty 2003<sup><xref ref-type="bibr" rid="bibr14-1352458512439437">14</xref></sup>) 66 (47 MS vs. 19 HC)</td>
<td>1.60 [0.75, 2.45], <italic>p</italic> = 0.0002<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">†</xref></sup></td>
<td>Not reported</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Inflexibility</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 122 (74 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>)</td>
<td>3.80 [1.20, 11.99], <italic>p</italic> = 0.02<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>26% vs. 9% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 26% vs. 9%</td>
</tr>
<tr>
<td>Impatience</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 122 (74 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>)</td>
<td>0.74 [0.32, 1.73], <italic>p</italic> = 0.49<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>22% vs. 27% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 22% vs. 27%</td>
</tr>
<tr>
<td>Insensitivity</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 122 (74 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>)</td>
<td>1.02 [0.37, 2.85], <italic>p</italic> = 0.97<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>15% vs. 14% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 15% vs. 14%</td>
</tr>
<tr>
<td>Lack of initiative</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 122 (74 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>)</td>
<td>0.76 [0.29, 1.99], <italic>p</italic> = 0.57<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>15% vs. 18% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 15% vs. 18%</td>
</tr>
<tr>
<td>Suspiciousness</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 122 (74 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>)</td>
<td>0.78 [0.28, 2.15], <italic>p</italic> = 0.63<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>13% vs. 16% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 13% vs. 16%</td>
</tr>
<tr>
<td>Dependency</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) 122 (74 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">b</xref></sup>)</td>
<td>0.84 [0.32, 2.17], <italic>p</italic> = 0.72<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>16% vs. 18% (Lima 2007<sup><xref ref-type="bibr" rid="bibr30-1352458512439437">30</xref></sup>) Mean: 16% vs. 18%</td>
</tr>
<tr>
<td colspan="7"><bold>BEHAVIOURAL IMPAIRMENTS</bold></td>
</tr>
<tr>
<td colspan="7"><bold>Adjustment disorders</bold></td>
</tr>
<tr>
<td>Adjustment disorder</td>
<td>1 (Espinola-Nadurille 2010<sup><xref ref-type="bibr" rid="bibr20-1352458512439437">20</xref></sup>) 74 (37 MS vs. 37 HC)</td>
<td>18.44 [1.01, 335.96], <italic>p</italic> = 0.05<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>19% vs. 0% (Espinola-Nadurille 2010<sup><xref ref-type="bibr" rid="bibr20-1352458512439437">20</xref></sup>) Mean: 19% vs. 0%</td>
<td>1 (Ron 1989<sup><xref ref-type="bibr" rid="bibr32-1352458512439437">32</xref></sup>) 164 (116 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">e</xref></sup>)</td>
<td>17.06 [1.00, 289.67], <italic>p</italic> = 0.05<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>15% vs. 0% (Ron 1989<sup><xref ref-type="bibr" rid="bibr32-1352458512439437">32</xref></sup>) Mean: 15% vs. 0%</td>
</tr>
<tr>
<td colspan="7"><bold>Anxiety disorders</bold></td>
</tr>
<tr>
<td>Obsessive-compulsive disorder</td>
<td>2 (Galeazzi 2005<sup><xref ref-type="bibr" rid="bibr23-1352458512439437">23</xref></sup>, Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 155 (70 MS vs. 85 HC)</td>
<td>2.96 [0.73, 11.98], <italic>p</italic> = 0.13<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>10% vs. 4% (Galeazzi 2005<sup><xref ref-type="bibr" rid="bibr23-1352458512439437">23</xref></sup>) 10% vs. 3% (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) Mean: 10% vs. 4%</td>
<td>1 (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 87 (42 MS vs. 45 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>1.70 [0.58, 4.97], <italic>p</italic> = 0.33<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>24% vs. 16% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) Mean: 24% vs. 16%</td>
</tr>
<tr>
<td>Panic disorder</td>
<td>1 (Galeazzi 2005<sup><xref ref-type="bibr" rid="bibr23-1352458512439437">23</xref></sup>) 100 (50 MS vs. 50 HC)</td>
<td>1.00 [0.19, 5.21], <italic>p</italic> = 1.00<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>6% vs. 6% (Galeazzi 2005<sup><xref ref-type="bibr" rid="bibr23-1352458512439437">23</xref></sup>) Mean: 6% vs. 6%</td>
<td>1 (Johnson 1996b<sup><xref ref-type="bibr" rid="bibr28-1352458512439437">28</xref></sup>) 75 (27 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>0.18 [0.01, 3.47], <italic>p</italic> = 0.26<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>0% vs. 8% (Johnson 1996b<sup><xref ref-type="bibr" rid="bibr28-1352458512439437">28</xref></sup>) Mean: 0% vs. 8%</td>
</tr>
<tr>
<td>Phobias</td>
<td>1 (Galeazzi 2005<sup><xref ref-type="bibr" rid="bibr23-1352458512439437">23</xref></sup>) 100 (50 MS vs. 50 HC)</td>
<td>2.14 [0.50, 9.07], <italic>p</italic> = 0.30<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>12% vs. 6% (Galeazzi 2005<sup><xref ref-type="bibr" rid="bibr23-1352458512439437">23</xref></sup>) Mean: 12% vs. 6%</td>
<td>1 (Johnson 1996b<sup><xref ref-type="bibr" rid="bibr28-1352458512439437">28</xref></sup>) 75 (27 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>0.42 [0.04, 3.99], <italic>p</italic> = 0.45<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>4% vs. 8% (Johnson 1996b<sup><xref ref-type="bibr" rid="bibr28-1352458512439437">28</xref></sup>) Mean: 4% vs. 8%</td>
</tr>
<tr>
<td colspan="7"><bold>Personality disorders</bold></td>
</tr>
<tr>
<td>Paranoid</td>
<td>1 (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 55 (20 MS vs. 35 HC)</td>
<td>11.33 [1.22, 105.54], <italic>p</italic> = 0.03<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>25% vs. 3% (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) Mean: 25% vs. 3%</td>
<td>1 (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 87 (42 MS vs. 45 OP<italic>d</italic>)</td>
<td>1.07 [0.06, 17.72], <italic>p</italic> = 0.96<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>2% vs 2% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) Mean: 2% vs. 2%</td>
</tr>
<tr>
<td>Narcissistic</td>
<td>1 (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 55 (20 MS vs. 35 HC)</td>
<td>0.56 [0.02, 14.42], <italic>p</italic> = 0.73<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>0% vs. 3% (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) Mean: 0% vs. 3%</td>
<td>1 (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 87 (42 MS vs. 45 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>1.08 [0.21, 5.66], <italic>p</italic> = 0.93<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>7% vs. 7% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) Mean: 7% vs. 7%</td>
</tr>
<tr>
<td>Histrionic</td>
<td>1 (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 55 (20 MS vs. 35 HC)</td>
<td>0.87 [0.07, 10.23], <italic>p</italic> = 0.91<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>5% vs. 6% (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) Mean: 5% vs. 6%</td>
<td>1 (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 87 (42 MS vs. 45 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>0.88 [0.25, 3.13], <italic>p</italic> = 0.84<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>12% vs. 13% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) Mean: 12% vs. 13%</td>
</tr>
<tr>
<td>Borderline</td>
<td>1 (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 55 (20 MS vs. 35 HC)</td>
<td>25.19 [1.31, 484.20], <italic>p</italic> = 0.03<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>25% vs. 0% (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) Mean: 25% vs. 0%</td>
<td>1 (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 87 (42 MS vs. 45 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>0.52 [0.05, 6.01], <italic>p</italic> = 0.60<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>2% vs. 4% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) Mean: 2% vs. 4%</td>
</tr>
<tr>
<td>Avoidant</td>
<td>1 (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 55 (20 MS vs. 35 HC)</td>
<td>Not estimable<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>0% vs. 0% (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) Mean: 0% vs. 0%</td>
<td>1 (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 87 (42 MS vs. 45 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>2.20 [0.19, 25.20], <italic>p</italic> = 0.53<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>5% vs. 2% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) Mean: 5% vs. 2%</td>
</tr>
<tr>
<td>Passive-aggressive</td>
<td>1 (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 55 (20 MS vs. 35 HC)</td>
<td>Not estimable<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>0% vs. 0% (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) Mean: 0% vs. 0%</td>
<td>1 (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 87 (42 MS vs. 45 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>0.79 [0.17, 3.75], <italic>p</italic> = 0.77<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>7% vs. 9% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) Mean: 7% vs. 9%</td>
</tr>
<tr>
<td>Dependent</td>
<td>1 (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 55 (20 MS vs. 35 HC)</td>
<td>0.56 [0.02, 14.42], <italic>p</italic> = 0.73<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>0% vs. 3% (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) Mean: 0% vs. 3%</td>
<td>1 (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 87 (42 MS vs. 45 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>1.60 [0.47, 5.50], <italic>p</italic> = 0.46<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>17% vs. 11% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) Mean: 17% vs. 11%</td>
</tr>
<tr>
<td colspan="7"><bold>Psychotic disorders</bold></td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>1 (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) 55 (20 MS vs. 35 HC)</td>
<td>Not estimable<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>0% vs. 0% (Johnson 1996a<sup><xref ref-type="bibr" rid="bibr27-1352458512439437">27</xref></sup>) Mean: 0% vs. 0%</td>
<td>2 (Pepper 199331, Surridge 196933) 234 (150 MS vs. 84 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">c</xref></sup>,<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>1.96 [0.20, 19.07], <italic>p</italic> = 0.56<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>2% vs. 0% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 1% vs. 0% (Surridge 1969<sup><xref ref-type="bibr" rid="bibr33-1352458512439437">33</xref></sup>) Mean: 2% vs. 0%</td>
</tr>
<tr>
<td>Delusional disorder</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 (Ron 1989<sup><xref ref-type="bibr" rid="bibr32-1352458512439437">32</xref></sup>) 164 (116 MS vs. 48 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">e</xref></sup>)</td>
<td>3.88 [0.20, 73.47], <italic>p</italic> = 0.37<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>3% vs. 0% (Ron 1989<sup><xref ref-type="bibr" rid="bibr32-1352458512439437">32</xref></sup>) Mean: 3% vs. 0%</td>
</tr>
<tr>
<td>Brief psychotic disorder</td>
<td>1 (Espinola-Nadurille 2010<sup><xref ref-type="bibr" rid="bibr20-1352458512439437">20</xref></sup>)</td>
<td>3.08 [0.12, 78.14], <italic>p</italic> = 0.49<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>3% vs. 0% (Espinola-Nadurille 2010<sup><xref ref-type="bibr" rid="bibr20-1352458512439437">20</xref></sup>) Mean: 3% vs. 0%</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td colspan="7"><bold>Somatoform disorders</bold></td>
</tr>
<tr>
<td>Somatization disorder</td>
<td>1 (Galeazzi 2005<sup><xref ref-type="bibr" rid="bibr23-1352458512439437">23</xref></sup>) 100 (50 MS vs.50 HC)</td>
<td>3.06 [0.12, 76.95], <italic>p</italic> = 0.50<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>2% vs. 0% (Galeazzi 200523) Mean: 2% vs. 0%</td>
<td>1 (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) 87 (42 MS vs. 45 OP<sup><xref ref-type="table-fn" rid="table-fn1-1352458512439437">d</xref></sup>)</td>
<td>2.20 [0.19, 25.20], <italic>p</italic> = 0.53<sup><xref ref-type="table-fn" rid="table-fn2-1352458512439437">¶</xref></sup></td>
<td>5% vs. 2% (Pepper 1993<sup><xref ref-type="bibr" rid="bibr31-1352458512439437">31</xref></sup>) Mean: 5% vs. 2%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458512439437">
<p>MS, multiple sclerosis; HC, Healthy controls; OP, Other patients than MS ( <sup>a</sup> = SLE patients; <sup>b</sup> = systemic inflammatory disorders patients without central nervous system disease; <sup>c</sup> = muscular dystrophy patients; <sup>d</sup> = chronic fatigue syndrome patients; <sup>e</sup> = physically disabled patients suffering from rheumatic or neurological diseases not involving the brain).</p>
</fn>
<fn id="table-fn2-1352458512439437">
<p>Statistical methods: <sup>*</sup> = Std. mean difference (IV, Fixed, 95% CI); <sup>‡</sup> = Std. mean difference (IV, Random, 95% CI); <sup>†</sup> = Mean difference (IV, Fixed, 95% CI); <sup>§</sup> = Mean difference (IV, Random, 95% CI); <sup>¶</sup> = Odds ratio (M-H, Fixed, 95% CI); <sup>#</sup> = Odds ratio (M-H, Random, 95% CI).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-1352458512439437">
<title>MS patients versus other patients</title>
<p>Meta-analyses revealed significantly more behavioural symptoms in MS patients than other patient groups in six out of 20 analyses. Specifically, patients with MS were found to show more apathy (<italic>p</italic> = 0.001), aggression (<italic>p</italic> = 0.004), inflexibility (<italic>p</italic> = 0.02), euphoria (<italic>p</italic> = 0.03), lack of insight (<italic>p</italic> = 0.04), and aberrant motor behaviour (<italic>p</italic> = 0.04) than other patients. Respectively, patients with MS had significantly more behavioural impairments than other patient groups in one out of 14 analyses. Specifically, MS patients were found to show more adjustment disorders (<italic>p</italic> = 0.05) than other patients.</p>
</sec>
<sec id="section13-1352458512439437">
<title>The prevalence of behavioural symptoms and impairments in MS</title>
<p>The mean prevalence percentages of behavioural symptoms and impairments among MS patients, healthy controls and other patients are summarized in <xref ref-type="fig" rid="fig2-1352458512439437">Figure 2</xref> (behavioural symptoms) and <xref ref-type="fig" rid="fig3-1352458512439437">Figure 3</xref> (behavioural impairments). The most common behavioural symptoms among patients with MS were lability (41%), irritability (38%), inflexibility (26%), aggression (23%), impatience (22%), and apathy (22%). The most common behavioural impairments among MS patients were adjustment disorder (17%) and obsessive-compulsive disorder (15%). Schizophrenia (1%), panic disorder (3%), avoidant personality disorder (3%), delusional disorder (3%), and brief psychotic disorder (3%) as well as somatization (1%), delusions (3%), and hallucinations (5%) were rare in MS.</p>
<fig id="fig2-1352458512439437" position="float">
<label>Figure 2.</label>
<caption>
<p>Mean prevalence percentages of behavioural symptoms among MS patients compared to healthy controls and other patient populations.</p>
<p>Pooled results from meta-analyses: *Significant difference between MS patients and healthy controls; ^Significant difference between MS patients and other patients. Prevalence percentages not reported for neuroticism, alexithymia, deficiencies in social cognition, aprosodia, paranoid ideation, psychoticism, and lack of empathy either for MS, healthy controls or other patients. Prevalence percentages not reported for lack of insight, lability, obsessiveness, somatization, inflexibility, aberrant motor behavior, impatience, dependency, social withdrawal, insensitivity, lack of initiative, suspiciousness, and blunted emotions for healthy controls.</p>
</caption>
<graphic xlink:href="10.1177_1352458512439437-fig2.tif"/>
</fig>
<fig id="fig3-1352458512439437" position="float">
<label>Figure 3.</label>
<caption>
<p>Mean prevalence percentages of behavioural impairments among MS patients compared with healthy controls and other patient populations.</p>
<p>Pooled results from meta-analyses: *Significant difference between MS patients and healthy controls; ^Significant difference between MS patients and other patients. Prevalence percentages not reported for delusional disorder for healthy controls and for brief psychotic disorder for other patients.</p>
</caption>
<graphic xlink:href="10.1177_1352458512439437-fig3.tif"/>
</fig>
<p>In the meta-analyses, MS patients were found to show significantly more impairment than healthy controls and other patients in four symptoms: 1) aggression (23%); 2) apathy (22%); 3) euphoria (12%); 4) lack of insight (11%), and in one impairment: adjustment disorder (17%).</p>
</sec>
</sec>
<sec id="section14-1352458512439437">
<title>Assessment methods</title>
<p>The behavioural assessment methods used in the original studies are summarized in <xref ref-type="table" rid="table3-1352458512439437">Table 3</xref>. The NEO Personality Inventory-Revised<sup><xref ref-type="bibr" rid="bibr34-1352458512439437">34</xref></sup> (NEO-PI-R) and the Neuropsychiatric Inventory<sup><xref ref-type="bibr" rid="bibr35-1352458512439437">35</xref></sup> (NPI) were used most frequently (<italic>n</italic> = 4/23, 17%). The Structured Clinical Interview for DSM-IV Axis I Disorders<sup><xref ref-type="bibr" rid="bibr36-1352458512439437">36</xref></sup> (SCID I) was used in three out of 23 (13%) studies. Studies on social cognition and theory of mind (<italic>n</italic> = 2) employed the Faux Pas Task and the Mind in the Eyes test.<sup><xref ref-type="bibr" rid="bibr37-1352458512439437">37</xref></sup> Other methods were used only in one study each.</p>
<table-wrap id="table3-1352458512439437" position="float">
<label>Table 3.</label>
<caption>
<p>Overview of the assessment methods used in evaluating behavioural symptoms and impairments in MS. Number of studies using the method in the studies reviewed and form of method used in the studies analysed.</p>
</caption>
<graphic alternate-form-of="table3-1352458512439437" xlink:href="10.1177_1352458512439437-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Behaviour assessment method</th>
<th align="center">Number of studies (%)<sup><xref ref-type="table-fn" rid="table-fn3-1352458512439437">*</xref></sup></th>
<th align="center">Form of the method used</th>
<th align="center">Description of the assessment method used</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEO Personality Inventory-Revised<sup><xref ref-type="bibr" rid="bibr34-1352458512439437">34</xref></sup> (NEO-PI-R)</td>
<td>4 (17%)</td>
<td>Subjective self-report in one and informant- report in one study.Results of two studies not used in the analyses.</td>
<td>A 240-item questionnaire evaluating five major domains of personality: 1) Neuroticism (anxiety, hostility, depression, self-consciousness, impulsiveness, vulnerability); 2) Extraversion (warmth, gregariousness, assertiveness, activity, excitement-seeking, positive emotions); 3) Openness to experience (fantasy, aesthetics, feelings, actions, ideas, values); 4) Agreeableness (trust, straightforwardness, altruism, compliance, modesty, tender-mindedness); and 5) Conscientiousness (competence, order, dutifulness, achievement, self-discipline, deliberation). Self- and informant- report forms.</td>
</tr>
<tr>
<td>Neuropsychiatric Inventory<sup><xref ref-type="bibr" rid="bibr35-1352458512439437">35</xref></sup> (NPI)</td>
<td>4 (17%)</td>
<td>Subjective informant- report in four studies.</td>
<td>The NPI is based on a structural interview with a caregiver assessing 10 neuropsychiatric domains: 1) Delusions; 2) Hallucinations; 3) Agitation/aggression; 4) Dysphoria; 5) Anxiety; 6) Euphoria; 7) Apathy; 8) Disinhibition; 9) Irritability/lability; and 10) Aberrant motor activity such as pacing and stereotyped behaviours. NPI scores are based on behaviours present in the past month. The symptom is scored by the caregiver, using operationalized criteria for frequency and severity.</td>
</tr>
<tr>
<td>Structured Clinical Interview for DSM-IV Axis I Disorders<sup><xref ref-type="bibr" rid="bibr36-1352458512439437">36</xref></sup> (SCID I)</td>
<td>3 (13%)</td>
<td>Objective clinician report in two studies.Results of one study not used in the analyses.</td>
<td>The SCID I is a semi-structured interview for making the major DSM-IV Axis I diagnoses including mood, psychotic, substance abuse, anxiety, somatoform, eating and adjustment disorders. It is modelled on a clinical interview during which various diagnostic hypotheses are successively tested by asking questions to elicit information relevant to the diagnostic criteria.</td>
</tr>
<tr>
<td>Faux Pas Tasks</td>
<td>2 (9%)</td>
<td>Questions to participant in two studies.</td>
<td>Short stories are read containing faux pas situation where a character says something socially inappropriate or something awkward or story ends with an ironic utterance. After reading the text, subjects are asked questions evaluating their detection of the faux pas and mental states of the protagonists.</td>
</tr>
<tr>
<td>Baron-Cohen’s Adult Eyes test / Mind in the Eyes test<sup><xref ref-type="bibr" rid="bibr37-1352458512439437">37</xref></sup></td>
<td>2 (9%)</td>
<td>Questions to participant in two studies.</td>
<td>36 photographs showing only the eyes of different actors/actresses portraying different complex mental states. For each set of eyes, subjects are asked to choose one out of four words that best describes what the person in the picture is thinking or feeling.</td>
</tr>
<tr>
<td>Affective Prosody Battery / Aprosodia Battery<sup><xref ref-type="bibr" rid="bibr38-1352458512439437">38</xref></sup></td>
<td>1 (4%)</td>
<td>Questions to participant in one study.</td>
<td>The Affective Prosody Battery assesses both production and comprehension of affective prosody. Word Repetition task includes 12 tokens of the sentence “I am going to the other movie” using two renditions each of neutral, happy, sad, surprised, angry and disinterested intonations, one with stress on “am” and the other with stress on “other”. The next two sets of the affective prosodic stimuli are exactly like the first except that one set uses a monosyllabic “sentence” (‘ba ba ba ba ba’) and the other an asyllabic sentence (‘aaaaahhhhh’) as carries of the different affects.</td>
</tr>
<tr>
<td>Baron-Cohen’s Adult Faces task<sup><xref ref-type="bibr" rid="bibr37-1352458512439437">37</xref></sup></td>
<td>1 (4%)</td>
<td>Questions to participant in one study.</td>
<td>20 photographs of the same actress, portraying different complex mental states. For each set of faces, subjects are asked to choose one out of two words best characterizing the feeling or thoughts expressed by the face.</td>
</tr>
<tr>
<td>Baron-Cohen’s Empathy Quotinent<sup><xref ref-type="bibr" rid="bibr39-1352458512439437">39</xref></sup></td>
<td>1 (4%)</td>
<td>Subjective self-report in one study.</td>
<td>A 60-item self-report questionnaire evaluating empathy and emotional reactivity. Responses are given on a 4-point scale ranging from ‘strongly agree’ to ‘strongly disagree’. Of 60 statements, 40 assess empathizing and 20 are filler items.</td>
</tr>
<tr>
<td>Behavioral Dyscontrol Scale<sup><xref ref-type="bibr" rid="bibr40-1352458512439437">40</xref></sup> (BDS)</td>
<td>1 (4%)</td>
<td>Subjective self-report in one study.</td>
<td>A 10-minute questionnaire based primarily on simple cognitive and motor tasks used by Alexander Luria<sup><xref ref-type="bibr" rid="bibr55-1352458512439437">55</xref></sup> in his studies of frontal lobe functioning. The BDS evaluates the individual’s capacity to regulate purposeful behaviour. The instrument is specifically created for the purpose of assessing individual’s ability to engage independently in activities of daily living (ADLs). The BDS is shown to be related to frontal lobe integrity, executive abilities and functional independence.</td>
</tr>
<tr>
<td>Center for Neurological Study – Lability Scale<sup><xref ref-type="bibr" rid="bibr41-1352458512439437">41</xref></sup> (CNS-LS)</td>
<td>1 (4%)</td>
<td>Subjective self-report in one study.</td>
<td>A few minutes’ self-report measure of affective lability/pathological laughing and crying. The CNS-LS evaluates affective dysregulation.</td>
</tr>
<tr>
<td>Clinical Interview Schedule<sup><xref ref-type="bibr" rid="bibr42-1352458512439437">42</xref></sup> (CIS)</td>
<td>1 (4%)</td>
<td>Objective clinician- report in one study.</td>
<td>The CIS is a semi-structured psychiatric interview covering non-psychotic symptoms particularly those associated with depression and anxiety.</td>
</tr>
<tr>
<td>Conversations and Insinuations (C&amp;I)</td>
<td>1 (4%)</td>
<td>Questions to participant in one study.</td>
<td>Video tasks that assess a subject’s ability to interpret the intention or the emotional state behind an explicit message conveyed by a character. During pauses the experimenter asks the subject a test question and the subject chooses the right answer from four alternative responses.</td>
</tr>
<tr>
<td>Diagnostic Interview Schedule<sup><xref ref-type="bibr" rid="bibr43-1352458512439437">43</xref></sup> (Q-DIS)</td>
<td>1 (4%)</td>
<td>Objective clinician- report in one study.</td>
<td>The Q-DIS is a structured psychiatric interview undertaken to provide the basis for a psychological assessment or psychiatric evaluation. The schedule covers more than 30 mental disorders and uses self-report scored by specially trained interviewers to assign a DSM diagnosis.</td>
</tr>
<tr>
<td>Dysexecutive Questionnaire<sup><xref ref-type="bibr" rid="bibr44-1352458512439437">44</xref></sup> (DEX)</td>
<td>1 (4%)</td>
<td>Results not used in the analyses.</td>
<td>A 20-item questionnaire evaluating possible behavioural changes as a result of the dysexecutive syndrome. Ratings of the frequency with which the particular behaviour occurs are made on a Likert-type scale (from ‘never’ to ‘often’). Self- and informant-report forms.</td>
</tr>
<tr>
<td>Frontal Systems Behavior Scale<sup><xref ref-type="bibr" rid="bibr45-1352458512439437">45</xref></sup> (FrSBe)</td>
<td>1 (4%)</td>
<td>Subjective informant- report in one study.</td>
<td>A 46-item questionnaire evaluating changes in behavioural functioning following brain injury or disease, emphasizing the various behavioural sequel of frontal lobe damage (apathy, disinhibition and executive dysfunction). The premordid (before the occurrence of illness) and current behaviour (after the occurrence of illness) are evaluated. Self- and informant-report forms.</td>
</tr>
<tr>
<td>Hogan Empathy Scale<sup><xref ref-type="bibr" rid="bibr46-1352458512439437">46</xref></sup> (HES)</td>
<td>1 (4%)</td>
<td>Subjective informant- report in one study.</td>
<td>A 64-item scale measuring the cognitive aspect of empathy. Items are answered as true or false. The range of scores is 0-64, with higher scores reflecting greater empathy in social situations. The HES is designed to measure the ability of an individual to see things from another person’s point of view. Self- and informant-report forms.</td>
</tr>
<tr>
<td>Hopkins Symptom Checklist-Revised<sup><xref ref-type="bibr" rid="bibr47-1352458512439437">47</xref></sup> (SCL-90-R)</td>
<td>1 (4%)</td>
<td>Subjective self-report in one study.</td>
<td>A 90-item self-report questionnaire assessing a broad range of psychologic/psychiatric symptomatology and consisting of nine subscales: 1) Depression; 2) Anxiety; 3) Somatization; 4) Obsessive-compulsive symptoms; 5) Inter-personal sensitivity; 6) Hostility; 7) Phobic anxiety; 8) Paranoid ideation; and 9) Psychoticism.</td>
</tr>
<tr>
<td>Iowa Scale of Personality Change<sup><xref ref-type="bibr" rid="bibr48-1352458512439437">48</xref></sup> (ISPC)</td>
<td>1 (4%)</td>
<td>Subjective informant- report in one study.</td>
<td>A 29-item questionnaire for patient’s informant about behavioural symptoms related to patient’s maladaptive functioning in affective, behavioural and social dimensions. Scale measures the extent of the change in the patient’s behaviour perceived by the informant in comparison to his/her premorbid status.</td>
</tr>
<tr>
<td>Millon Clinical Multiaxial Inventory II<sup><xref ref-type="bibr" rid="bibr49-1352458512439437">49</xref></sup> (MCMI-II)</td>
<td>1 (4%)</td>
<td>Subjective self-report in one study.</td>
<td>A 175-item self-report questionnaire evaluating specific disorders outlined in the DSM-IV. True-false questions are modelled on four scales: 1) Personality disorder scales; 2) Clinical syndromes scales; 3) Response indicators (which determine the patient’s response style and can detect random responding); and 4) Grossman personality facet scales. The MCMI-II is particularly sensitive to Axis II disorders but can also identify Axis I pathology.</td>
</tr>
<tr>
<td>Personality Diagnostic Questionnaire –Revised<sup><xref ref-type="bibr" rid="bibr50-1352458512439437">50</xref></sup> (PDQ-R)</td>
<td>1 (4%)</td>
<td>Subjective self-report in one study.</td>
<td>A 163-item true-false questionnaire assessing the presence of personality disorders. The PDQ-R includes items for making a specific DSM III-R personality disorder diagnosis, as well as yielding a total score intended as an index of overall personality disturbance.</td>
</tr>
<tr>
<td>Psychiatric interview</td>
<td>1 (4%)</td>
<td>Objective clinician- report in one study.</td>
<td>The psychiatric interview can be divided into four stages: 1) Building an alliance with the patient; 2) Psychiatric history; 3) Diagnostic evaluation; and 4) Treatment plan formulation. The interviewer should come to understand the patient’s behaviours, emotions, and experiences, as well as psychological, social, religious influences and motivations, through verbal and nonverbal communication with the patient.<sup><xref ref-type="bibr" rid="bibr56-1352458512439437">56</xref></sup></td>
</tr>
<tr>
<td>Short-form Revised Eysenck Personality Questionnaire<sup><xref ref-type="bibr" rid="bibr51-1352458512439437">51</xref></sup> (EPQR-S)</td>
<td>1 (4%)</td>
<td>Subjective self-report in one study.</td>
<td>A 48-item self-report questionnaire evaluating the three personality dimensions of extraversion, neuroticism and psychoticism, as well as the lie scale (designed to assess the degree of socially desirable responding). A dichotomous response format is used with respondents ticking ‘Yes’ or ‘No’.</td>
</tr>
<tr>
<td>Strange stories Task</td>
<td>1 (4%)</td>
<td>Questions to participant in one study.</td>
<td>16 short stories to be read by the subject. Half of the stories (Strange Stories-Mental) require an appreciation of a character’s mental state, like desires and thought, whereas the other eight stories (Strange Stories-Physical) involve making a physical interference.</td>
</tr>
<tr>
<td>Toronto Alexithymia Scale<sup><xref ref-type="bibr" rid="bibr52-1352458512439437">52</xref></sup> (TAS)</td>
<td>1 (4%)</td>
<td>Subjective self-report in one study.</td>
<td>A 26-item self-report questionnaire evaluating alexithymia. Alexithymia refers to people who have trouble identifying and describing emotions and who tend to minimize emotional experience and focus attention externally. The TAS has three subscales: 1) Difficulty describing feelings; 2) Difficulty identifying feelings; and 3) Externally-oriented thinking. Items are rated using a 5-point Likert-type scale from ‘strongly disagree’ to ‘strongly agree’.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1352458512439437">
<label>*</label>
<p>Also other measures were used in all studies.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The behavioural assessment methods used in analyses were based on patient self-report in nine, informant-report in eight, and clinician-report in five studies. In addition, eight studies employed methods consisting of different questions for participants which required, for example, interpreting the emotional state of the character.</p>
</sec>
</sec>
<sec id="section15-1352458512439437" sec-type="discussion">
<title>Discussion</title>
<p>The present study evaluated the prevalence of subjective behavioural symptoms and objective impairments in MS by means of a systematic review of studies conducted in the field. Some 23 original controlled studies were identified in a comprehensive and systematic literature search, the sample consisting of altogether 1117 patients with MS. MS patients were found to manifest significantly more behavioural symptoms such as aggression (23%), apathy (22%), euphoria (12%) and lack of insight (11%) as well as impairments such as adjustment disorder (17%) than healthy controls and other patients with SLE, chronic fatigue syndrome and muscular dystrophy. Thus, these symptoms and impairments seem to represent the most frequent behavioural manifestations in MS, excluding depression which was not evaluated in this review.</p>
<p>Pooled results in the meta-analyses revealed that patients with MS have a high morbidity of behavioural symptoms, especially when compared with healthy controls: in 13 out of 20 behavioural symptoms significant differences were found. When MS patients were compared with other patient populations, the differences in behavioural symptoms were less obvious. However, patients with MS reported more impairment in six out of 20 behavioural symptoms than patients with other diagnoses. According to these analyses, several behavioural symptoms are not MS specific, but more general symptoms of chronic diseases. The findings on the prevalence rates in MS compared with other diseases have to be taken as preliminary because only in six studies this kind of comparison was made. Objective behavioural impairments were not as common as subjective symptoms: MS patients were found to show more impairment in three out of 11 disorders than healthy controls, and in one out of 14 disorders than other patient groups. Thus, in comparisons between MS patients and healthy controls or other patients 48% of subjective symptoms and 16% of objective impairments significant differences were found.</p>
<p>The most common behavioural symptoms reported by MS patients were lability (41%), irritability (38%), inflexibility (26%), aggression (23%), impatience (22%), and apathy (22%), and the most common behavioural disorders were adjustment disorder (17%) and obsessive–compulsive disorder (15%). On the contrary, somatization, delusions, and hallucinations, as well as schizophrenia, panic disorder, avoidant personality disorder, delusional disorder, and brief psychotic disorder were rare manifestations of the disease. Thus, severe mental disorders seem to be less frequent than changes in behaviour, manner of reaction, and way of action in MS.</p>
<p>The general characteristics of the MS sample in the present review represent the overall MS population relatively well. Firstly, on average, 66% of participants were women, corresponding to the known gender distribution in MS. Secondly, the mean age of participants (39.9 years) follows the general incidence peak age of the disease. However, the patients represented relatively mild disability, as can be seen in the EDSS scores (range 1.5–5.1, mean 3.2). In addition, most of the patients had a relapsing–remitting course of the disease. Therefore, the results of the current review are not fully applicable to all MS patients, especially to those with a more disabling form of the disease or disease courses other than the relapsing–remitting one. The MS and control groups were similar with respect to demographic factors, and therefore these important prognostic indicators did not significantly bias the results.</p>
<p>There is a high degree of comorbidity among different neuropsychiatric disorders.<sup><xref ref-type="bibr" rid="bibr53-1352458512439437">53</xref></sup> Even so, studies on psychiatric disturbances in MS have usually focused on one or only a few neuropsychiatric symptoms. Assessment methods used in the original studies varied considerably. Eighteen out of 23 (78%) assessment methods were used in only one of the studies. The most commonly used outcome measures were the NEO-PI-R<sup><xref ref-type="bibr" rid="bibr34-1352458512439437">34</xref></sup> and the NPI,<sup><xref ref-type="bibr" rid="bibr35-1352458512439437">35</xref></sup> both of which were used in four out of the 23 (17%) studies.</p>
<p>The diagnosis of behavioural disorders cannot be based on the evaluation scales only, without a structured psychiatric interview following the international criteria of DSM-IV or ICD-10. In 16 out of 23 (70%) studies, behavioural impairments were not evaluated as a clinical entity, but instead the symptoms were evaluated on the basis of different self- or informant-reported scales. Specifically, analyses on the prevalence of behavioural symptoms and impairments were based on methods using patient self-report in nine (30%), informant-report in eight (27%) and clinician-report in five (17%) studies. Most patients in this review had a relatively mild stage of the disease. It is possible that, especially in the early phases of the disease, the frequency of neuropsychiatric symptoms is overestimated when only self-report assessment methods are used. On the other hand, as the disease progresses and self-awareness decreases,<sup><xref ref-type="bibr" rid="bibr3-1352458512439437">3</xref>,<xref ref-type="bibr" rid="bibr54-1352458512439437">54</xref></sup> the prevalence of neuropsychiatric symptoms based on self-report may become underestimated. Then again, the sole use of semi-structured interviews may be subject to interviewer bias and poor reliability. In clinical practice, in addition to careful and comprehensive structured psychiatric interview and observation, the use of standardized multi-symptom assessment methods specifically designed for use in neurological disorders with neuropsychiatric manifestations, such as the NPI, increases the probability of detecting behavioural problems.</p>
<p>There are some limitations in the present review, and thus the findings have to be considered as directional. Firstly, the number of included studies was relatively small. Secondly, the evaluated behavioural symptoms and disorders as well as the assessment methods were heterogeneous. Thirdly, subjective behavioural symptoms and objective impairments are not commensurable. However, because of small sample size, it was not reasonable to limit the review only to subjective symptoms or objective disorders alone. Behavioural symptoms are under-recognized in MS and cannot be predicted from the overall disability or other external disease markers. The present review offers preliminary information about the frequency of behavioural problems and possible methods to evaluate these problems in MS.</p>
<p>In conclusion, objective behavioural impairments and especially subjective symptoms, seem to be relatively frequent among MS patients. In particular, aggression, apathy, adjustment disorder, euphoria, and lack of insight seem to be typical in MS. Severe mental disorders, such as psychosis, hallucinations and schizophrenia, are clearly less common than changes in behaviour, manner of reaction, and way of action in MS. The high frequency of behavioural problems among patients with MS underlines the importance of focusing on the emotional disturbances, in addition to the neurological manifestations, in patient management. Multi-symptom, standardized assessment tools should be used, in addition to comprehensive structured psychiatric interview and observation, to detect neuropsychiatric manifestations. It is important to evaluate behavioural problems both with subjective and objective evaluation methods to be able to define whether patients experience more problems with behaviour regulation than can be found with objective assessment tools.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors declare that they have no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512439437">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghaffar</surname><given-names>O</given-names></name>
<name><surname>Feinstein</surname><given-names>A</given-names></name>
</person-group>. <article-title>The neuropsychiatry of multiple sclerosis: a review of recent developments</article-title>. <source>Curr Opin Psychiatry</source> <year>2007</year>; <volume>20</volume>: <fpage>278</fpage>-<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512439437">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langdon</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Cognition in multiple sclerosis</article-title>. <source>Curr Opin Neurology</source> <year>2011</year>; <volume>24</volume>: <fpage>244</fpage>-<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512439437">
<label>3.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Feinstein</surname><given-names>A</given-names></name>
</person-group> <source>The clinical neuropsychiatry of multiple sclerosis</source>. <edition>2nd ed.</edition> <publisher-loc>New York</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>, <year>2007</year>.</citation>
</ref>
<ref id="bibr4-1352458512439437">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paparrigopoulos</surname><given-names>T</given-names></name>
<name><surname>Ferentinos</surname><given-names>P</given-names></name>
<name><surname>Kouzoupis</surname><given-names>A</given-names></name>
<name><surname>Koutsis</surname><given-names>G</given-names></name>
<name><surname>Papadimitriou</surname><given-names>GN</given-names></name>
</person-group>. <article-title>The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour</article-title>. <source>Int Rev Psychiatry</source> <year>2010</year>; <volume>22</volume>: <fpage>14</fpage>-<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512439437">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dalton</surname><given-names>EJ</given-names></name>
<name><surname>Heinrichs</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Depression in multiple sclerosis: a quantitative review of the evidence</article-title>. <source>Neuropsychology</source> <year>2005</year>; <volume>19</volume>: <fpage>152</fpage>-<lpage>158</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512439437">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filley</surname><given-names>CM</given-names></name>
</person-group>. <article-title>White matter: beyond focal disconnection</article-title>. <source>Neurol Clin</source> <year>2011</year>; <volume>29</volume>: <fpage>81</fpage>-<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512439437">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Antonak</surname><given-names>R</given-names></name>
<name><surname>Livneh</surname><given-names>H</given-names></name>
</person-group>. <article-title>Psychological adaptation to disability and its investigation among persons with multiple sclerosis</article-title>. <source>Soc Sci Med</source> <year>1995</year>; <volume>40</volume>: <fpage>1099</fpage>-<lpage>1108</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512439437">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poser</surname><given-names>CM</given-names></name>
<name><surname>Paty</surname><given-names>DW</given-names></name>
<name><surname>Scheinberg</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>New diagnostic criteria for multiple sclerosis: guidelines for research protocols</article-title>. <source>Ann Neurol</source> <year>1983</year>; <volume>13</volume>: <fpage>227</fpage>-<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512439437">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDonald</surname><given-names>WI</given-names></name>
<name><surname>Compston</surname><given-names>A</given-names></name>
<name><surname>Edan</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2001</year>; <volume>50</volume>: <fpage>121</fpage>-<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512439437">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haiman</surname><given-names>G</given-names></name>
<name><surname>Pratt</surname><given-names>H</given-names></name>
<name><surname>Miller</surname><given-names>A</given-names></name>
</person-group>. <article-title>Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect</article-title>. <source>J Neurol Sci</source> <year>2008</year>; <volume>271</volume>: <fpage>137</fpage>-<lpage>147</lpage>. *</citation>
</ref>
<ref id="bibr11-1352458512439437">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ouellet</surname><given-names>J</given-names></name>
<name><surname>Scherzer</surname><given-names>PB</given-names></name>
<name><surname>Rouleau</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Assessment of social cognition in patient with multiple sclerosis</article-title>. <source>J Int Neuropsychol Soc</source> <year>2010</year>; <volume>16</volume>: <fpage>287</fpage>-<lpage>296</lpage>. *</citation>
</ref>
<ref id="bibr12-1352458512439437">
<label>12.</label>
<citation citation-type="book">
<article-title>Review Manager (RevMan) Version 5.1. [Computer program]</article-title>. <publisher-loc>Copenhagen</publisher-loc>: <publisher-name>The Nordic Cochrane Centre. The Cochrane Collaboration</publisher-name>, <year>2011</year>.</citation>
</ref>
<ref id="bibr13-1352458512439437">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Banati</surname><given-names>M</given-names></name>
<name><surname>Sandor</surname><given-names>J</given-names></name>
<name><surname>Mike</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Social cognition and Theory of Mind in patients with relapsing-remitting multiple sclerosis</article-title>. <source>Eur J Neurol</source> <year>2010</year>; <volume>17</volume>: <fpage>426</fpage>-<lpage>433</lpage>. *</citation>
</ref>
<ref id="bibr14-1352458512439437">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beatty</surname><given-names>WW</given-names></name>
<name><surname>Orbelo</surname><given-names>DM</given-names></name>
<name><surname>Sorocco</surname><given-names>KH</given-names></name>
<name><surname>Ross</surname><given-names>ED</given-names></name>
</person-group>. <article-title>Comprehension of affective prosody in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2003</year>; <volume>9</volume>: <fpage>148</fpage>-<lpage>153</lpage>. *</citation>
</ref>
<ref id="bibr15-1352458512439437">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benedict</surname><given-names>RHB</given-names></name>
<name><surname>Priore</surname><given-names>RL</given-names></name>
<name><surname>Miller</surname><given-names>C</given-names></name>
<name><surname>Munschauer</surname><given-names>F</given-names></name>
<name><surname>Jacobs</surname><given-names>L</given-names></name>
</person-group>. <article-title>Personality disorder in multiple sclerosis correlates with cognitive impairment</article-title>. <source>J Neuropsychiatry Clin Neurosci</source> <year>2001</year>; <volume>13</volume>: <fpage>70</fpage>-<lpage>76</lpage>. *</citation>
</ref>
<ref id="bibr16-1352458512439437">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benedict</surname><given-names>RHB</given-names></name>
<name><surname>Wahlig</surname><given-names>E</given-names></name>
<name><surname>Bakshi</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change</article-title>. <source>J Neurol Sci</source> <year>2005</year>; <volume>231</volume>: <fpage>29</fpage>-<lpage>34</lpage>. *</citation>
</ref>
<ref id="bibr17-1352458512439437">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chiaravalloti</surname><given-names>ND</given-names></name>
<name><surname>Deluca</surname><given-names>J</given-names></name>
</person-group>. <article-title>Assessing the behavioral consequences of multiple sclerosis: an application of the Frontal Systems Behavior Scale (FrSBe)</article-title>. <source>Cogn Behav Neurol</source> <year>2003</year>; <volume>16</volume>: <fpage>54</fpage>-<lpage>67</lpage>. *</citation>
</ref>
<ref id="bibr18-1352458512439437">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daly</surname><given-names>E</given-names></name>
<name><surname>Komaroff</surname><given-names>AL</given-names></name>
<name><surname>Bloomingdale</surname><given-names>K</given-names></name>
<name><surname>Wilson</surname><given-names>S</given-names></name>
<name><surname>Albert</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Neuropsychological function in patients with chronic fatigue syndrome, multiple sclerosis, and depression</article-title>. <source>Appl Neuropsychol</source> <year>2001</year>; <volume>8</volume>: <fpage>12</fpage>-<lpage>22</lpage>. *</citation>
</ref>
<ref id="bibr19-1352458512439437">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Diaz-Olavarrieta</surname><given-names>C</given-names></name>
<name><surname>Cummings</surname><given-names>JL</given-names></name>
<name><surname>Velazquez</surname><given-names>J</given-names></name>
<name><surname>Garcia De Al Cadena</surname><given-names>C</given-names></name>
</person-group>. <article-title>Neuropsychiatric manifestations of multiple sclerosis</article-title>. <source>J Neuropsychiatry Clin Neurosci</source> <year>1999</year>; <volume>11</volume>: <fpage>51</fpage>-<lpage>57</lpage>. *</citation>
</ref>
<ref id="bibr20-1352458512439437">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Espinola-Nadurille</surname><given-names>M</given-names></name>
<name><surname>Colin-Piana</surname><given-names>R</given-names></name>
<name><surname>Ramirez-Bermudez</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Mental disorders in Mexican patients with multiple sclerosis</article-title>. <source>J Neuropsychiatry Clin Neurosci</source> <year>2010</year>; <volume>22</volume>: <fpage>63</fpage>-<lpage>69</lpage>. *</citation>
</ref>
<ref id="bibr21-1352458512439437">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Figved</surname><given-names>N</given-names></name>
<name><surname>Klevan</surname><given-names>G</given-names></name>
<name><surname>Myhr</surname><given-names>KM</given-names></name>
<etal/>
</person-group>. <article-title>Neuropsychiatric symptoms in patients with multiple sclerosis</article-title>. <source>Acta Psychiatr Scand</source> <year>2005</year>; <volume>112</volume>: <fpage>463</fpage>-<lpage>468</lpage>. *</citation>
</ref>
<ref id="bibr22-1352458512439437">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fishman</surname><given-names>I</given-names></name>
<name><surname>Benedict</surname><given-names>RHB</given-names></name>
<name><surname>Bakshi</surname><given-names>R</given-names></name>
<name><surname>Priore</surname><given-names>R</given-names></name>
<name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
</person-group>. <article-title>Construct validity and frequency of euphoria sclerotic in multiple sclerosis</article-title>. <source>J Neuropsychiatry Clin Neurosci</source> <year>2004</year>; <volume>16</volume>: <fpage>350</fpage>-<lpage>356</lpage>. *</citation>
</ref>
<ref id="bibr23-1352458512439437">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galeazzi</surname><given-names>GM</given-names></name>
<name><surname>Ferrari</surname><given-names>S</given-names></name>
<name><surname>Giaroli</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy</article-title>. <source>Neurol Sci</source> <year>2005</year>; <volume>26</volume>: <fpage>255</fpage>-<lpage>262</lpage>. *</citation>
</ref>
<ref id="bibr24-1352458512439437">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gioia</surname><given-names>MC</given-names></name>
<name><surname>Cerasa</surname><given-names>A</given-names></name>
<name><surname>Valentino</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Neurofunctional correlated of personality traits in relapsing-remitting multiple sclerosis: An fMRI study</article-title>. <source>Brain Cogn</source> <year>2009</year>; <volume>71</volume>: <fpage>320</fpage>-<lpage>327</lpage>. *</citation>
</ref>
<ref id="bibr25-1352458512439437">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grigsby</surname><given-names>J</given-names></name>
<name><surname>Kravcisin</surname><given-names>N</given-names></name>
<name><surname>Ayarbe</surname><given-names>SD</given-names></name>
<name><surname>Busenbark</surname><given-names>D</given-names></name>
</person-group>. <article-title>Prediction of deficits in behavioral self-regulation among persons with multiple sclerosis</article-title>. <source>Arch Phys Med Rehabil</source> <year>1993</year>; <volume>74</volume>: <fpage>1350</fpage>-<lpage>1353</lpage>. *</citation>
</ref>
<ref id="bibr26-1352458512439437">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>JD</given-names></name>
<name><surname>Phillips</surname><given-names>LH</given-names></name>
<name><surname>Beatty</surname><given-names>WW</given-names></name>
<etal/>
</person-group>. <article-title>Evidence for deficits in facial affect recognition and theory of mind in multiple sclerosis</article-title>. <source>J Int Neuropsychol Soc</source> <year>2009</year>; <volume>15</volume>: <fpage>277</fpage>-<lpage>285</lpage>. *</citation>
</ref>
<ref id="bibr27-1352458512439437">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>SK</given-names></name>
<name><surname>Deluca</surname><given-names>J</given-names></name>
<name><surname>Natelson</surname><given-names>BH</given-names></name>
</person-group>. <article-title>Personality dimensions in the chronic fatigue syndrome: a comparison with multiple sclerosis and depression</article-title>. <source>J Psychiat Res</source> <year>1996a</year>; <volume>30</volume>: <fpage>9</fpage>-<lpage>20</lpage>. *</citation>
</ref>
<ref id="bibr28-1352458512439437">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>SK</given-names></name>
<name><surname>Deluca</surname><given-names>J</given-names></name>
<name><surname>Natelson</surname><given-names>BH</given-names></name>
</person-group>. <article-title>Depression in fatiguing illness: comparing patients with chronic fatigue syndrome, multiple sclerosis and depression</article-title>. <source>J Affect Disord</source> <year>1996b</year>; <volume>39</volume>: <fpage>21</fpage>-<lpage>30</lpage>. *</citation>
</ref>
<ref id="bibr29-1352458512439437">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>SK</given-names></name>
<name><surname>Lange</surname><given-names>G</given-names></name>
<name><surname>Tiersky</surname><given-names>L</given-names></name>
<name><surname>Deluca</surname><given-names>J</given-names></name>
<name><surname>Natelson</surname><given-names>BH</given-names></name>
</person-group>. <article-title>Health-related personality variables in chronic fatigue syndrome and multiple sclerosis</article-title>. <source>J Chronic Fatig Synd</source> <year>2001</year>; <volume>8</volume>: <fpage>41</fpage>-<lpage>52</lpage>. *</citation>
</ref>
<ref id="bibr30-1352458512439437">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lima</surname><given-names>FS</given-names></name>
<name><surname>Simioni</surname><given-names>S</given-names></name>
<name><surname>Bruggimann</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Perceived behavioral changes in early multiple sclerosis</article-title>. <source>Behav Neurol</source> <year>2007</year>; <volume>18</volume>: <fpage>81</fpage>-<lpage>90</lpage>. *</citation>
</ref>
<ref id="bibr31-1352458512439437">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pepper</surname><given-names>CM</given-names></name>
<name><surname>Krupp</surname><given-names>LB</given-names></name>
<name><surname>Friedberg</surname><given-names>F</given-names></name>
<name><surname>Doscher</surname><given-names>C</given-names></name>
<name><surname>Coyle</surname><given-names>PK</given-names></name>
</person-group>. <article-title>A comparison of neuropsychiatric characteristics in chronic fatigue syndrome, multiple sclerosis, and major depression</article-title>. <source>J Neuropsychiatry Clin Neurosci</source> <year>1993</year>; <volume>5</volume>: <fpage>200</fpage>-<lpage>205</lpage>. *</citation>
</ref>
<ref id="bibr32-1352458512439437">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ron</surname><given-names>MA</given-names></name>
<name><surname>Logsdail</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Psychiatric morbidity in multiple sclerosis: a clinical and MRI study</article-title>. <source>Psychol Med</source> <year>1989</year>; <volume>19</volume>: <fpage>887</fpage>-<lpage>895</lpage>. *</citation>
</ref>
<ref id="bibr33-1352458512439437">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Surridge</surname><given-names>D</given-names></name>
</person-group>. <article-title>An investigation into some psychiatric aspects of multiple sclerosis</article-title>. <source>Brit J Psychiat</source> <year>1969</year>; <volume>115</volume>: <fpage>749</fpage>-<lpage>764</lpage>. *</citation>
</ref>
<ref id="bibr34-1352458512439437">
<label>34.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Costa</surname><given-names>PT</given-names></name>
<name><surname>MCcrae</surname><given-names>RR</given-names></name>
</person-group>. <source>Professional manual for the revised NEO Personality Inventory and NEO five-factor inventory</source>. <publisher-loc>Odessa, FL</publisher-loc>, <publisher-name>Psychological Assessment Resources</publisher-name>, <year>1992</year>.</citation>
</ref>
<ref id="bibr35-1352458512439437">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cummings</surname><given-names>JL</given-names></name>
<name><surname>Mega</surname><given-names>MS</given-names></name>
<name><surname>Gray</surname><given-names>K</given-names></name>
<name><surname>Rosemberg-Thompson</surname><given-names>S</given-names></name>
<name><surname>Gornbein</surname><given-names>T</given-names></name>
</person-group>. <article-title>The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia</article-title>. <source>Neurology</source> <year>1994</year>; <volume>44</volume>: <fpage>2308</fpage>-<lpage>2314</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512439437">
<label>36.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>First</surname><given-names>MB</given-names></name>
<name><surname>Spitzer</surname><given-names>RL</given-names></name>
<name><surname>Gibbon</surname><given-names>M</given-names></name>
<name><surname>Williams</surname><given-names>JB</given-names></name>
</person-group>. <source>Structured Clinical Interview for the DSM-IV Axis I Disorders</source>. <publisher-loc>Washington, DC</publisher-loc>, <publisher-name>American Psychiatric Press</publisher-name>, <year>1999</year>.</citation>
</ref>
<ref id="bibr37-1352458512439437">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baron-Cohen</surname><given-names>S</given-names></name>
<name><surname>Wheelwright</surname><given-names>S</given-names></name>
<name><surname>Jolliffe</surname><given-names>T</given-names></name>
</person-group>. <article-title>Is there a “language of the eyes”? Evidence from normal adults and adults with autism or Asperger syndrome</article-title>. <source>Vis Cogn</source> <year>1997</year>; <volume>4</volume>: <fpage>311</fpage>-<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr38-1352458512439437">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ross</surname><given-names>ED</given-names></name>
<name><surname>Thompson</surname><given-names>R</given-names></name>
<name><surname>Yenkosky</surname><given-names>J</given-names></name>
</person-group>. <article-title>Lateralization of affective prosody in brain and callosal integration of hemispheric language functions</article-title>. <source>Brain Lang</source> <year>1997</year>; <volume>56</volume>: <fpage>27</fpage>-<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr39-1352458512439437">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lawrence</surname><given-names>EJ</given-names></name>
<name><surname>Shaw</surname><given-names>P</given-names></name>
<name><surname>Baker</surname><given-names>D</given-names></name>
<name><surname>Baron-Cohen</surname><given-names>S</given-names></name>
<name><surname>David</surname><given-names>S</given-names></name>
</person-group>. <article-title>Measuring empathy: reliability and validity of the Empathy Quotient</article-title>. <source>Psychol Med</source> <year>2004</year>; <volume>34</volume>: <fpage>911</fpage>-<lpage>924</lpage>.</citation>
</ref>
<ref id="bibr40-1352458512439437">
<label>40.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Grigsby</surname><given-names>J</given-names></name>
<name><surname>Kaye</surname><given-names>K</given-names></name>
</person-group> <source>The Behavioral Dyscontrol Scale: Manual</source>. <publisher-loc>Denver, CO</publisher-loc>: <publisher-name>Authors</publisher-name>, <year>1992</year>.</citation>
</ref>
<ref id="bibr41-1352458512439437">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stan</surname><given-names>RM</given-names></name>
<name><surname>Louise</surname><given-names>SG</given-names></name>
<name><surname>Mark</surname><given-names>BB</given-names></name>
<name><surname>Edward</surname><given-names>JK</given-names></name>
<name><surname>Richard</surname><given-names>AS</given-names></name>
</person-group>. <article-title>A self report measure of affective lability</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>1997</year>; <volume>63</volume>: <fpage>89</fpage>-<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr42-1352458512439437">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldberg</surname><given-names>DP</given-names></name>
<name><surname>Cooper</surname><given-names>B</given-names></name>
<name><surname>Eastwood</surname><given-names>MR</given-names></name>
<name><surname>Kedward</surname><given-names>HB</given-names></name>
<name><surname>Shepherd</surname><given-names>M</given-names></name>
</person-group>. <article-title>A standardized psychiatric interview for use in community surveys</article-title>. <source>Br J Prev Soc Med</source> <year>1970</year>; <volume>24</volume>: <fpage>18</fpage>-<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr43-1352458512439437">
<label>43.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Marcus</surname><given-names>S</given-names></name>
<name><surname>Robbins</surname><given-names>LW</given-names></name>
<name><surname>Bucholz</surname><given-names>K</given-names></name>
</person-group> <source>Quick Diagnostic Interview Schedule III-R</source>, <publisher-loc>version 1. St Louis</publisher-loc>: <publisher-name>St. Louis University School of Medicine</publisher-name>, <year>1990</year>.</citation>
</ref>
<ref id="bibr44-1352458512439437">
<label>44.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>BA</given-names></name>
<name><surname>Alderman</surname><given-names>N</given-names></name>
<name><surname>Burgess</surname><given-names>PW</given-names></name>
<name><surname>Emslie</surname><given-names>H</given-names></name>
<name><surname>Evans</surname><given-names>J</given-names></name>
</person-group> <source>Behavioural Assessment of the Dysexecutive Syndrome (BADS) Manual</source>. <publisher-loc>Bury St Edmonds, England</publisher-loc>: <publisher-name>Thames Valley Test Company</publisher-name>, <year>1996</year>.</citation>
</ref>
<ref id="bibr45-1352458512439437">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grace</surname><given-names>J</given-names></name>
<name><surname>Stout</surname><given-names>JC</given-names></name>
<name><surname>Malloy</surname><given-names>PF</given-names></name>
</person-group>. <article-title>Assessing frontal lobe behavioral syndromes with the Frontal Lobe Personality Scale</article-title>. <source>Assessment</source> <year>1999</year>; <volume>6</volume>: <fpage>269</fpage>-<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr46-1352458512439437">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hogan</surname><given-names>R</given-names></name>
</person-group>. <article-title>Development of an empathy scale</article-title>. <source>J Consult Clin Psychol</source> <year>1969</year>; <volume>33</volume>: <fpage>307</fpage>-<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr47-1352458512439437">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Derogatis</surname><given-names>LR</given-names></name>
<name><surname>Melisaratos</surname><given-names>N</given-names></name>
</person-group>. <article-title>The brief symptom inventory</article-title>. <source>Psychol Med</source> <year>1983</year>; <volume>13</volume>: <fpage>595</fpage>-<lpage>605</lpage>.</citation>
</ref>
<ref id="bibr48-1352458512439437">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barrash</surname><given-names>J</given-names></name>
<name><surname>Anderson</surname><given-names>SW</given-names></name>
<name><surname>Jones</surname><given-names>RD</given-names></name>
<name><surname>Wefel</surname><given-names>JS</given-names></name>
<name><surname>Tranel</surname><given-names>D</given-names></name>
</person-group>. <article-title>Iowa scales of personality change: reliability and validity</article-title>. <source>J Int Neuropsychol Soc</source> <year>1997</year>; <volume>3</volume>: <fpage>27</fpage>-<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr49-1352458512439437">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McCann</surname><given-names>JT</given-names></name>
</person-group>. <article-title>A multitrait-multimethod analysis of the MCMI-II clinical syndrome scales</article-title>. <source>J Pers Assess</source> <year>1990</year>; <volume>55</volume>: <fpage>465</fpage>-<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr50-1352458512439437">
<label>50.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Hyler</surname><given-names>SE</given-names></name>
<name><surname>Reider</surname><given-names>RO</given-names></name>
</person-group> <source>PDQ-R: Personality Disorders Questionnaire-Revised</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>New York State Psychiatric Institute</publisher-name>, <year>1987</year>.</citation>
</ref>
<ref id="bibr51-1352458512439437">
<label>51.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Eysenck</surname><given-names>HJ</given-names></name>
<name><surname>Eysenck</surname><given-names>SBG</given-names></name>
</person-group>. <source>Manual of the Eysenck personality scales</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Hodder and Stoughton</publisher-name>, <year>1991</year>.</citation>
</ref>
<ref id="bibr52-1352458512439437">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>GJ</given-names></name>
<name><surname>Bagby</surname><given-names>RM</given-names></name>
<name><surname>Ryan</surname><given-names>DP</given-names></name>
<name><surname>Parker</surname><given-names>JDA</given-names></name>
<name><surname>Doody</surname><given-names>KF</given-names></name>
<name><surname>Keefe</surname><given-names>P</given-names></name>
</person-group>. <article-title>Criterion validity of the Toronto Alexithymia Scale</article-title>. <source>Psychosom Medi</source> <year>1988</year>; <volume>50</volume>: <fpage>500</fpage>-<lpage>509</lpage>.</citation>
</ref>
<ref id="bibr53-1352458512439437">
<label>53.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Tasman</surname><given-names>A</given-names></name>
<name><surname>Mohr</surname><given-names>WK</given-names></name>
</person-group>. <source>Fundamentals of psychiatry</source>. <publisher-loc>West Sussex</publisher-loc>: <publisher-name>John Wiley &amp; Sons Ltd</publisher-name>, <year>2011</year>.</citation>
</ref>
<ref id="bibr54-1352458512439437">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carone</surname><given-names>DA</given-names></name>
<name><surname>Benedict</surname><given-names>RHB</given-names></name>
<name><surname>Munschauer</surname><given-names>FE</given-names></name>
<name><surname>Fishman</surname><given-names>I</given-names></name>
<name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
</person-group>. <article-title>Interpreting patient/informant discrepancies of reported cognitive symptoms in MS</article-title>. <source>J Int Neuropsychol Soc</source> <year>2005</year>; <volume>11</volume>: <fpage>574</fpage>-<lpage>583</lpage>.</citation>
</ref>
<ref id="bibr55-1352458512439437">
<label>55.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Luria</surname><given-names>AR</given-names></name>
</person-group> <source>Higher Cortical Functions in Man</source>. <edition>2nd ed.</edition> <publisher-loc>New York</publisher-loc>: <publisher-name>Basic Books</publisher-name>, <year>1980</year>.</citation>
</ref>
<ref id="bibr56-1352458512439437">
<label>56.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Rhoads</surname><given-names>J</given-names></name>
</person-group> <source>Clinical Consult for Psychiatric Mental Health Care</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer Publishing Company, LLC</publisher-name>, <year>2011</year>. *Studies included in the review.</citation>
</ref>
</ref-list>
</back>
</article>